Cancer treatment in India is set to become more affordable for patients using certain medicines after the National Pharmaceutical Pricing Authority (NPPA) revised the maximum retail prices of 543 cancer drug brands and pack sizes. The updated prices are scheduled to take effect on November 9, 2026, following a government move to limit trade margins on 137 selected anti-cancer medicines.
The changes include substantial reductions for some generic cancer drugs. However, the price revisions are not uniform, and several high-cost branded treatments remain unchanged.
Some Cancer Medicines See Price Cuts of More Than 90%
One of the biggest reductions affects a brand of palbociclib, a medicine used in the treatment of certain breast cancers. Its listed price for a particular pack has fallen from approximately ₹40,421 to ₹2,720, representing a reduction of about 93.3%.
The price of a thiotepa chemotherapy product has also been revised downward, from around ₹80,072 to ₹7,150 per vial. Other medicines, including dasatinib, lenvatinib, abiraterone and olaparib, have also seen reductions in certain brands and pack sizes.
The actual savings will depend on the medicine, its formulation, the prescribed brand and the quantity required for treatment. The largest reductions apply to specific products and should not be interpreted as a price cut of the same size across all cancer medicines.
Why Are Medicine Prices Being Revised?
The latest changes follow a decision to cap trade margins at 30% of the maximum retail price for 137 identified non-scheduled anti-cancer medicines. The measure is intended to reduce excessive markups across the medicine distribution chain.
The issue of medicine affordability has also come under scrutiny in the Supreme Court, where judges questioned the wide gap between the prices at which some medicines are supplied to retailers and the amounts patients are charged.
The proceedings have raised broader questions about whether existing price controls provide sufficient protection to people who need costly treatments.
Expensive Cancer Brands May Remain Unchanged
Despite the reductions, not every cancer medicine will become cheaper under the revised list. Some costly branded treatments, including Keytruda, have not received a price reduction in this revision.
This distinction matters because cancer treatment costs vary widely depending on the drug, the type of cancer, the prescribed treatment plan and the duration of therapy. A reduction in one medicine’s price does not necessarily translate into an equivalent reduction in a patient’s total treatment bill.
What Patients Should Know Before November 9
Patients and families should check the updated price of their specific medicine once the revised rates take effect. The medicine’s name, strength, formulation and pack size must match when comparing prices.
Patients should also request an itemised bill and discuss any proposed change in brand or formulation with their treating doctor or pharmacist. Cancer medicines should not be changed or stopped without appropriate medical advice.
The revised prices represent an important development in India’s efforts to improve access to cancer treatment, although the financial benefit for each patient will depend on which medicines they use and whether the revised prices are reflected in their final bills.
